At a glance
- Originator Bristol-Myers Squibb
- Class Antirheumatics
- Mechanism of Action Matrix metalloproteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatic disorders
Most Recent Events
- 20 Jun 2001 No-Development-Reported for Rheumatic disorders in USA (Unknown route)
- 10 Oct 1997 Preclinical development for Rheumatic disorders in USA (Unknown route)
- 29 Sep 1997 New profile